HS

Henry Schein IncNASDAQ HSIC Stock Report

Last reporting period 28 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

8.958

Middle

Exchange

XNAS - Nasdaq

HSIC Stock Analysis

HS

Avoid

Based on Eyestock quantitative analysis, HSIC`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

35/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-36.4 %

Greatly overvalued

Market cap $B

8.958

Dividend yield

Shares outstanding

131.28 B

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. The company is headquartered in Melville, New York and currently employs 22,000 full-time employees. The Company’s segments include Health care distribution and Technology and value-added services. The Health care distribution segment is combining its global dental and medical businesses, distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. The Technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. The firm distributes its products from approximately 29 located distribution centers.

View Section: Eyestock Rating